volixibat
Small molecule
Evidence outlook
Primary Sclerosing Cholangitis: topline reported 2026-05-04
The sponsor reported topline results on 2026-05-04 (VISTAS Phase 2b met primary endpoint in PSC). The announcement is listed under Regulatory events.
Latest reported trial: VISTAS (NCT04663308) · Phase 2 · met primary endpoint · grade pending
Also in development:Primary Biliary Cholangitis · Phase 2
Company guidance: topline data expected first quarter of 2027 (Mirum Pharmaceuticals, Inc., 3 Nov 2026). “We expect topline data from our PBC study of volixibat in the first quarter of 2027.” Source ↗
Company guidance: regulatory filing expected first half of 2027 (NCT04663308; Mirum Pharmaceuticals, Inc., 3 Nov 2026). “We expect to submit a potential NDA to the FDA in the first half of 2027 for approval of volixibat for the treatment of pruritus due to PSC based on the VISTAS study and supporting data, but regulatory authorities still may not agree with our interpretation of the safety or efficacy data from the study and may not grant approval.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
VISTAS NCT04663308 · Primary Sclerosing Cholangitis The Phase 2b VISTAS study enrolled 182 participants with primary sclerosing cholangitis and pruritus. The sponsor reports that it met its primary endpoint, with statistically significant reductions in pruritus; the registry has no posted results. Caveat: this result is taken from a company announcement, not from the trial registry or a peer-reviewed publication. Treat it as the sponsor's own statement. Registry: NCT04663308 | 2 | Mean change in the daily itch scores using the Adult Itch Reported Outcome (Adult ItchRO) questionnaire (Baseline through to Week 28) 2026-02-20 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other Ileal bile acid transporter (IBAT) drugs
maralixibat. Compare all 2 Ileal bile acid transporter (IBAT) drugs
1 other tracked programme targets this mechanism, 1 of them ahead of this one.
This drug's own stage for Primary Biliary Cholangitis: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Volixibat: this drug | Phase 2 | Small molecule | Ileal bile acid transporter (IBAT) | not yet graded | No reviewed efficacy summary in this indication | |
| Elafibranor (Iqirvo) | Approved | Small molecule | PPAR-alpha/PPAR-delta | Partial signal | NCT04526665: Percentage of Participants With Response to Treatment Based on Cholestasis Response at Week 52 (At Week 52): Elafibranor 80 mg 50.9 Percentage of participants (95% CI 41.6 to 60.2) | Placebo 3.8 Percentage of participants (95% CI 1 to 12.8) | |
| Maralixibat (Livmarli) | Approved(overall) | Small molecule | Ileal bile acid transporter (IBAT) | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Seladelpar (Livdelzi) | Approved | Small molecule | PPAR-delta | Partial signal | NCT06060665: Primary endpoint, composite ALP normalization at week 52: significantly more patients than placebo (Gilead, 2026-06-02). NCT04620733: Composite biochemical response at Month 12 (ALP below 1.67 x ULN, ALP reduction of at least 15% and total bilirubin at or below ULN), seladelpar (n=128) vs placebo (n=65): 61.7% vs 20.0%; risk difference 41.7 percentage points (95% CI 27.7 to 53.4), p < 0.0001 (Cochran-Mantel-Haenszel; CT.gov posted results). | |
| Saroglitazar (Lipaglyn) | Phase 3 | Small molecule | PPAR-alpha/PPAR-gamma | Partial signal | NCT05133336: Primary composite biochemical response at 52 weeks: treatment difference 48.5% favouring saroglitazar 1 mg over placebo (P<0.001) (2025-08-29). | |
| Pemafibrate (Parmodia) | Phase 2 | Small molecule | PPAR-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Setanaxib | Phase 2 | Small molecule | NOX1/4 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow volixibat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
January 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent